AGO2

Across TCGA pan-cancer cohorts, AGO2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AGO2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AGO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGO2 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where AGO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.261	0.599	.001	34	view →
HNSC	DFS	Tertile	All	0.266	1.000	.011	14	view →
GBM	DFS	Quartile	All	0.849	0.498	.009	4	view →
UCEC	OS	Quartile	III,IV	0.323	1.000	.042	4	view →
CCRCC	OS	Median	All	1.000	0.755	.041	2	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AGO2–PDAC (DFS)

Open the PDAC breakdown →